25988 Acceptability of 20% aminolevulinic acid photodynamic therapy for treatment of actinic keratoses on the upper extremities in a phase 3, randomized, vehicle-controlled trial

Introduction: Aminolevulinic acid (ALA) 20% solution photodynamic therapy (PDT) is indicated for targeted treatment of actinic keratosis (AK) on the face, scalp, and upper extremities. In a phase 3 study (NCT02137785), ALA 20% solution–PDT at baseline and week 8 using lesion-targeted treatment with 3-hour occluded incubation was superior to vehicle-PDT for AK clearance of the upper extremities; 118/134 (88%) patients receiving ALA-PDT vs 55/131 (25%) patients receiving vehicle-PDT were very or moderately satisfied with efficacy.